FDA Commissioner Steps Down Amid Policy Disputes Over E-Cig Approvals

The sudden departure of Dr. Marty Makary from his post as Commissioner of the U.S. Food and Drug Administration has sent ripples through Washington’s health policy circles. Makary’s resignation, announced on Tuesday, came just days after reports surfaced that the White House had moved to remove him from his role.

On Friday, multiple outlets reported that the Trump administration had approved plans to dismiss Makary, a move that preceded his voluntary exit over the weekend. The resignation was formally communicated via text message, a method that drew public attention when the message was shared on social media. The text read: "Dr. President Trump, Please accept my resignation, effective today."

President Trump later addressed Makary’s decision in a Truth Social post, acknowledging his contributions while framing the departure as a mutual acknowledgment of the administration’s policy directions. "He has done a great job at the FDA," Trump wrote. "A hard worker, respected by all, and he will go on to have an outstanding career in medicine."

The timing of Makary’s resignation has fueled speculation about the underlying tensions between his office and the White House. Earlier this month, reports emerged that the administration had pushed for the approval of flavored e-cigarettes—an issue that had become a point of contention within the FDA. Makary, a vocal advocate for stricter tobacco regulations, had previously clashed with officials over the agency’s stance on vaping products.

Public health advocates and industry observers are now questioning how Makary’s exit will impact the FDA’s regulatory approach. His tenure was marked by efforts to curb youth vaping through stringent oversight of e-cigarette manufacturers. The approval of fruity-flavored vaping products, in particular, had been a flashpoint, with critics arguing that such decisions undermined public health goals.

As the administration prepares to name a successor, stakeholders are closely watching for signals about the FDA’s future direction. Will the agency continue to prioritize public health initiatives, or will the new leadership align more closely with the administration’s policy preferences? The answers to these questions will shape the next chapter of tobacco regulation in the United States.

Makary’s departure marks another high-profile exit from a federal agency amid shifting political priorities. His resignation underscores the delicate balance between regulatory independence and executive oversight—a tension that has only grown more pronounced in recent years.